Endocrine Abstracts

Contents

• 17th Annual Multidisciplinary NET Medical Symposium NANETS 2024
• • Basic Science
  • • Development of innovative in vitro and in vivo patient-derived cancer models for translational studies in G1/G2 gastroenteropancreatic neuroendocrine tumors

      ea0108b1
    • Spatial transcriptomics of multifocal ileal neuroendocrine tumors reveals tumor heterogeneity based on tumor microenvironment and new biomarkers

      ea0108b2
    • Investigating the role of oncometabolites in von hippel lindau disease-related pancreatic neuroendocrine neoplasms

      ea0108b3
    • Hedgehog signaling drives glial cell plasticity and oncogenic reprogramming in gastroenteropancreatic neuroendocrine tumors

      ea0108b4
    • Single-nucleus transcriptome profiling of enterochromaffin cells in SI-NET patients

      ea0108b5
    • A novel hormone based anti-SSTR bispecific T-cell engager for the treatment of neuroendocrine tumorrs

      ea0108b6
    • The role of cancer associated fibroblasts on the growth of pancreatic neuroendocrine tumors

      ea0108b7
    • Surface calreticulin induction by doxorubicin in a patient derived xenograft model of pancreatic neuroendocrine carcinoma

      ea0108b8
    • Establishment of a long term gastric neuroendocrine tumor organoid and matched patient derived xenograft

      ea0108b9
    • Development of GEP-NEN patient derived organoids for long term culture and therapy screening

      ea0108b10
    • Phosphoproteomic mass spectrometry reveals a novel therapeutic target in well-differentiated gastroenteropancreatic neuroendocrine tumors

      ea0108b11
    • Combination of angiogenesis and HIF-2[alpha] blockade: synergistic pair worth exploring in neuroendocrine tumors

      ea0108b12
    • Transcriptome alterations in pancreatic neuroendocrine tumors among those living with adverse social determinants of health

      ea0108b13
    • Deletion of notch1 inhibits pancreatic neuroendocrine tumor growth in vivo

      ea0108b14
    • CDK4/6 and MEK are actionable, therapeutic targets in pancreatic and lung neuroendocrine tumors (NETs)

      ea0108b15
  • Applied Basic Science
  • • Comparison of pulmonary versus extra-pulmonary small cell neuroendocrine carcinomas demonstrate distinct genomic alterations

      ea0108b16
    • Molecular landscape of extra-pulmonary small cell neuroendocrine carcinomas based on site of origin

      ea0108b17
    • Uncovering genomic differences between small and large cell extra-pulmonary neuroendocrine carcinomas

      ea0108b18
    • Activity of nab-sirolimus alone or in combination with cabozantinib, octreotide, or talazoparib in nonclinical neuroendocrine tumor models

      ea0108b19
    • Spatial analysis of the tumor microenvironment in pancreatic neuroendocrine tumors

      ea0108b20
    • Therapeutic targeting of SDHB-deficient tumors

      ea0108b21
    • TILs from panNET liver metastases: in search of novel adoptive transfer strategies for the treatment of NETs

      ea0108b22
    • A novel nonpeptide drug conjugate (NDC) for the treatment of somatostatin receptor 2-expressing tumors

      ea0108b23
    • Cell-free methylation signatures non-invasively distinguish patients with MEN1 and provide insights into the biology underlying metastatic dpNETs

      ea0108b24
    • NETest® 2.0 - a decade of innovation in neuroendocrine tumor/neoplasm diagnostics

      ea0108b25
    • Leveraging cell mass measurements to assess drug efficacy for gastroenteropancreatic neuroendocrine tumor liver metastases and advanced adrenocortical carcinoma

      ea0108b26
    • Use of patient-derived pre-clinical models to identify new and effective treatments for neuroendocrine tumors

      ea0108b27
    • Stratification of neuroendocrine tumors for ecto-5-nucleotidase expression for clinical trials

      ea0108b28
  • Clinical - Chemo/SSA/Biologics
  • • NP-101 in combination with nivolumab and ipilimumab in metastatic extra-pulmonary neuroendocrine carcinomas (EP-NECs): a pilot study

      ea0108c1
    • Preliminary clinical activity of surufatinib combined with octreotide LAR in patients with G1/2 gastroenteropancreatic neuroendocrine tumor (GEP-NET)

      ea0108c2
    • Prolonged response to dabrafenib/trametinib in metastatic well-differentiated grade 3 pancreatic neuroendocrine tumor (NET G3) with BRAF V600E mutation

      ea0108c3
    • Comparison of survival outcomes and hypoglycemic control in patients receiving systemic therapy for malignant insulinoma

      ea0108c4
    • Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: results from a phase 2, randomized, parallel-group study

      ea0108c5
    • Evaluation of switching SSAs on GI-NET progression - experience at an academic medical center

      ea0108c6
    • Cabozantinib therapy in patients with previously treated well differentiated grade 3 neuroendocrine tumors (G3 NETs)

      ea0108c7
    • Temozolomide induced hypermutation in pancreatic neuroendocrine tumors: a case series

      ea0108c8
    • Updated results of CABINET trial/alliance A021602: cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy

      ea0108c9
    • RZ358 (ersodetug) as a novel therapy for hypoglycemia due to tumor hyperinsulinism: outcomes from an expanded access program for compassionate use

      ea0108c10
    • Survivin and DLL-3 as predictors of survival in low-grade neuroendocrine tumor patients

      ea0108c11
    • Updated phase 1 data for the DLL3/CD3 IgG-like T-cell engager BI 764532 in DLL3-positive tumors: focus on extrapulmonary neuroendocrine carcinomas

      ea0108c12
    • Patterns of long-term remission or apparent cure in a cohort of patients with grade 3 neuroendocrine neoplasms (NENs)

      ea0108c13
    • Approach integrating ERCP with radiofrequency ablation for long-term management for metastatic pancreatic NET to biliary tree as klatskin tumor

      ea0108c14
    • RECIST for the real world: impact of response evaluation criteria in solid tumors compared to standard radiology reports on physician decisions and patient satisfaction

      ea0108c15
    • Targeted alpha therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors

      ea0108c16
    • ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: phase 1b safety/efficacy

      ea0108c17
    • DNA damage repair mutational status's effect on Lu-177-DOTATATE in combination with olaparib in metastatic SSTR+ GI neuroendocrine tumor: preliminary results

      ea0108c18
    • Safety of lutetium-177 DOTATATE treatment in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases

      ea0108c19
  • Clinical - Nuclear Medicine/Interventional Radiology/Imaging
  • • Imaging, clinical, and safety outcomes in metastatic neuroendocrine tumor patients treated with peptide receptor radionuclide therapy in the midwestern USA

      ea0108c20
    • Effect of absorbed dose on toxicity and tumor response of Lu-177-DOTATATE with olaparib in gastroenteropancreatic neuroendocrine patients: preliminary results

      ea0108c21
    • Multicenter clinical registry of patients with a neuroendocrine tumor (NET) diagnosis receiving Lu-177-DOTATATE

      ea0108c22
    • Neuroendocrine tumor (NET) progression of disease during or within one year after completion of therapy with Lu-177-DOTATATE

      ea0108c23
    • Evaluating time to treatment start for patients receiving peptide receptor radioligand therapy

      ea0108c24
    • Does liver tumor morphology predict outcomes after LDT, PRRT or captem?

      ea0108c25
    • Incidence and characterization of carcinoid crises post embolization of neuroendocrine tumor liver metastases

      ea0108c26
    • A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive metastases

      ea0108c27
    • Liver-directed therapy for metastatic neuroendocrine carcinoma and grade 3 well-differentiated neuroendocrine tumors

      ea0108c28
    • Initial outcomes of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 3 liver-dominant metastatic neuroendocrine tumors

      ea0108c29
    • Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: a comprehensive analysis of expression in the era of somatostatin receptor PET imaging

      ea0108c30
    • First-line efficacy of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: phase 3 NETTER-2 subgroup analysis

      ea0108c31
    • Outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in patients with malignant pheochromocytoma (PCC) and paraganglioma (PGL): a single institution retrospective study

      ea0108c32
    • Corticosteroid prophylaxis did not decrease tumor flare reaction in high-risk neuroendocrine tumors patients treated with 177Lu-DOTATATE

      ea0108c33
    • Peptide receptor radionuclide therapy with 177 Lu-DOTATATE: a single center experience

      ea0108c34
    • Small bowel obstruction incidence in Lu177 PRRT patients had no impact on overall survival

      ea0108c35
    • Safety and efficacy of peptide receptor radionuclide therapy in thymic neuroendocrine neoplasms: a single-institutional case series

      ea0108c36
    • Preliminary safety and efficacy data of [212Pb]VMT-[alpha]-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)

      ea0108c37
    • Radioactivity in drained body cavity fluid following peptide receptor radionuclide therapy with 177Lu DOTATATE in patients with advanced neuroendocrine tumors

      ea0108c38
    • Dosimetry-guided 131I-mIBG therapy in a hemodialysis-dependent paraganglioma patient

      ea0108c39
    • Implementation of dosimetry in clinical Lu177-DOTATATE therapy

      ea0108c40
  • Clinical - Surgery/Applied Pathology
  • • Long-term survival outcomes after minimally invasive surgery for ileal neuroendocrine tumors

      ea0108c41
    • Loss of MGMT protein expression by immunohistochemistry is associated with response to capecitabine/temozolomide in neuroendocrine neoplasms (NENs)

      ea0108c42
    • To treat or not to treat: resection of primary pancreatic neuroendocrine tumors in the metastatic setting

      ea0108c43
    • Incidence and prognostic analysis of neuroendocrine differentiation in CRC, GC, ESCC and BTC cohorts

      ea0108c44
    • Interaction between race and insurance coverage for gastroenteropancreatic neuroendocrine tumor outcomes

      ea0108c45
    • Clinical utility of preoperative DOTATATE-PET in small bowel neuroendocrine tumors

      ea0108c46
    • Response after neoadjuvant chemotherapy for pancreatic neuroendocrine tumors

      ea0108c47
    • Impact of hospital type and location on survival outcomes for patients with well-differentiated G1/G2 pancreatic neuroendocrine tumors

      ea0108c48
    • National trends in surgical management of T1N0 well-differentiated pancreatic neuroendocrine tumors (PNET) and age-specific survival

      ea0108c49